http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007012661-A8

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9f1e3c7f9bc2140527cd58aa9f8a009f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bec0ce8e73e5954935089af1dea21933
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_225037e994b5edf93aac4a1f4db484fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b6139cd07643d522d609e4257e51b75
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164
filingDate 2006-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6fa7bab8d312f3fbbabc39a2b6dc93e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5470a735eb69fd1ccf9a768f35d4a777
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cc41b21565e88224f05b7d1c1a2358d
publicationDate 2007-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2007012661-A8
titleOfInvention Hydantoin derived compounds and use thereof as mchr-1 antagonists
abstract The invention concerns compounds of general formula (I) wherein: Ar1, L1, R1, R2, R3, R4, R5, R6, L2, Q, and n are such as defined in the claims, as well as the method for preparing same. The invention also concerns the use of the compounds of formula (I) as medicine, and more particularly for preparing a medicine for treating obesity and related diseases, an anorexiant and/or a medicine for losing weight, a medicine for treating depression and/or anxiety, and more generally a medicine for treating a disease associated with MHC (melanin-concentrating hormone ) receptors.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9108944-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9481664-B2
priorityDate 2005-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10006
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422601319
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16167454
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419549379
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCB7TWR3

Total number of triples: 31.